India Glycols Q1 FY27 Earnings Call Transcript Released
India Glycols reported a strong Q1 FY27 with net revenue at ₹1,130 crore (up 9%) and EBITDA at ₹170 crore (up 13%). The company received NCLT approval for demerger of Spirits, Bio-Fuel, and Bio Pharma businesses. Spirits revenue grew 5.3%, Chemicals 20.6%, and Ennature Bio Pharma revenue surged 65%. Finance costs reduced to ₹25 crore.
The announcement details strong financial performance, significant business restructuring via demerger, and optimistic future outlook and targets. These are material events that are likely to significantly influence investor perception and the company's strategic direction.
The company reported strong financial results for Q1 FY27 with double-digit growth in revenue, EBITDA, and PAT. Positive developments include NCLT approval for business restructuring, improved margins, and significant growth in key segments like Ennature Bio Pharma. The management provided encouraging outlook and future aspirations.
India Glycols Limited (IGL) has released the transcript of its Q1 FY27 Earnings Conference Call, which was held on August 14, 2026. The call featured insights from key management personnel, including Mr. Rupark Sarswat (CEO), Mr. Anand Singhal (CFO), and Mr. Manoj Kumar Rai (ED & COO, IGL Spirits Limited).
During the call, the company reported a strong start to FY27 with double-digit growth in gross revenue, EBITDA, and PAT. Net revenue stood at ₹1,130 crores, up 9%, with a record EBITDA of ₹170 crores, up 13%, and PAT up 32%. The business restructuring plan, which received NCLT approval, is progressing as per schedule, with an effective date to be communicated.
The Spirits business recorded a revenue of ₹361 crores, up 5.3%, and EBITDA growth of 14.2%. The Chemicals segment saw revenues increase by 20.6% to ₹362 crores, driven by growth in bio-glycols, green solvents, and performance chemicals. Bio-Fuel reported revenue of ₹323 crores with EBIT increasing 19% to ₹27 crores. Ennature Bio Pharma reported its best-ever quarter with revenue rising 65% year-on-year and EBITDA increasing 188%, supported by new customer acquisitions and product launches.
Finance costs declined to ₹25 crores from ₹45 crores in Q1 FY26 due to debt reduction. The company highlighted a consistent improvement in EBITDA margin, rising from 9.6% in FY22 to 15.5% in FY26. The NCLT sanctioned the scheme of arrangement on July 17, 2026, for the demerger of Spirits, Bio-Fuel, and Bio Pharma undertakings into dedicated companies. India Glycols Limited will continue with bio-based chemicals and specialty chemicals, IGL Spirits Limited will house potable spirits and Bio-Fuel, and Ennature Bio Pharma will include nutraceuticals, APIs, and biopolymers.
Segment-wise performance for Q1 FY27: IGL Spirits reported net revenue of ₹694 crores and EBITDA of ₹120 crores (17.3% margin). India Glycols (chemicals) reported net revenue of ₹345 crores (up 24% YoY) and EBITDA of ₹40 crores (11.6% margin). Ennature Bio Pharma reported net revenue of ₹90 crores (up 53% YoY) and EBITDA of ₹10 crores (11.1% margin). Consolidated net revenue was ₹1,130 crores (up 9% YoY) with EBITDA at ₹170 crores (up 13% YoY).
For the Spirits business, the outlook includes planned launches in the deluxe whiskey and semi-premium vodka segments, a focus on the white spirits business, and strategic partnerships, such as with Amrut. Geographical expansion is also a key focus, aiming for an all-India footprint. The company targets an EBITDA in excess of ₹500 crores for FY27 and aims to be debt-free from FY28 onwards, with a long-term EBITDA target of over ₹1,000 crores in 4-5 years.
The Chemicals business aims for an EBITDA of approximately ₹400 crores and revenue of ₹2,500 crores in the next 4-5 years, leveraging its strength in bio-based specialty chemicals and innovation. Ennature Bio Pharma aspires to achieve an EBITDA of ₹130-₹150 crores over the next 4-5 years, driven by growth in nicotine and branded nutraceuticals.
The company also discussed the impact of geopolitical events, noting both headwinds and tailwinds. While crude oil price spikes had a positive impact on the ethylene oxide business, volatility in freight rates and raw material availability posed challenges.
What to do with a filing like this
India Glycols Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by India Glycols Limited. Read the original for the full detail.